Elucidating the precise pharmacological mechanism of action (MOA) of naturally transpiring compounds is often demanding. Even though Tarselli et al. (60) designed the primary de novo artificial pathway to conolidine and showcased this naturally developing compound effectively suppresses responses to equally chemically induced and inflammation-derived pain, the pharmacologic target https://www.proleviate.com/post/conolidine-an-alternative-natural-pain-relief-to-replace-traditional-painkillers